Current clinical perspectives on myocardial angiogenesis.
Currently accepted modalities of treatment for atherosclerotic coronary artery disease (CAD) include pharmacological therapy, and revascularization with either bypass surgery or percutaneous coronary intervention (PCI). Similarly, conventional treatment of congestive heart failure (HF) is limited to medical therapy, temporary assist devices and in a select few, cardiac transplantation. A significant subset of patients with severe symptomatic CAD and end stage HF is not eligible for these traditional methods of treatment. In spite of maximal medical and revascularization therapy, these patients may not get adequate symptomatic relief. After a decade of investigations, gene therapy is emerging as a promising therapeutic option for this group of patients. This review discusses myocardial angiogenesis as a therapeutic modality in these patients including therapeutic angiogenesis with growth factors and cell transplantation.
Mukherjee
Debabrata
D
Division of Cardiology, The University of Michigan, Ann Arbor, MI 48109-0311, USA. dmukherj@umich.edu
D000818:Animals; D017690:Cell Transplantation; D003327:Coronary Disease / Q000628:therapy*; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D006133:Growth Substances / Q000378:metabolism; D006801:Humans; D017202:Myocardial Ischemia; D009204:Myocardial Revascularization; D018919:Neovascularization, Physiologic; D013997:Time Factors
D006133:Growth Substances